# Accuray Inc: financial statements, quarterly

ARAY · Nasdaq · CIK 1138723 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Jun 30

Pages: [Overview](/companies/aray.md) · [Financials](/companies/aray/financials.md) · [Filings](/companies/aray/filings.md) · [Insiders](/companies/aray/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/aray/financials.md?period=annual).

## Income statement

| Line item | Unit | Q1 FY2024 (2023-09-30) | Q2 FY2024 (2023-12-31) | Q3 FY2024 (2024-03-31) | Q4 FY2024 (2024-06-30) | Q1 FY2025 (2024-09-30) | Q2 FY2025 (2024-12-31) | Q3 FY2025 (2025-03-31) | Q4 FY2025 (2025-06-30) | Q1 FY2026 (2025-09-30) | Q2 FY2026 (2025-12-31) | Q3 FY2026 (2026-03-31) | Q4 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [104](/filings/0000950170-24-122358.md) | [107](/filings/0000950170-25-014485.md) | [101](/filings/0000950170-25-062744.md) | [134 d](/filings/0001437749-26-004219.md) | [102](/filings/0001437749-26-004220.md) | [116](/filings/0001437749-26-004221.md) | [113](/filings/0001437749-26-015199.md) | [128 d](/filings/0001437749-26-029098.md) | [93.9](/filings/0001437749-26-004220.md) | [102](/filings/0001437749-26-004221.md) | [105](/filings/0001437749-26-015199.md) | [101 d](/filings/0001437749-26-029098.md) |
| Cost of revenue | $m | [64.4](/filings/0000950170-24-122358.md) | [71.3](/filings/0000950170-25-014485.md) | [72.1](/filings/0000950170-25-062744.md) | [95.8 d](/filings/0001437749-26-004219.md) | [67.1](/filings/0001437749-26-004220.md) | [74.3](/filings/0001437749-26-004221.md) | [81.6](/filings/0001437749-26-015199.md) | [88.6 d](/filings/0001437749-26-029098.md) | [67.4](/filings/0001437749-26-004220.md) | [78.2](/filings/0001437749-26-004221.md) | [79.6](/filings/0001437749-26-015199.md) | [65.8 d](/filings/0001437749-26-029098.md) |
| Gross profit | $m | [39.5](/filings/0000950170-24-122358.md) | [35.9](/filings/0000950170-25-014485.md) | [29.1](/filings/0000950170-25-062744.md) | [38.5 d](/filings/0001437749-26-004219.md) | [34.5](/filings/0001437749-26-004220.md) | [41.9](/filings/0001437749-26-004221.md) | [31.6](/filings/0001437749-26-015199.md) | [39.0 d](/filings/0001437749-26-029098.md) | [26.5](/filings/0001437749-26-004220.md) | [24.1](/filings/0001437749-26-004221.md) | [25.3](/filings/0001437749-26-015199.md) | [35.1 d](/filings/0001437749-26-029098.md) |
| Research and development | $m | [14.0](/filings/0000950170-24-122358.md) | [15.3](/filings/0000950170-25-014485.md) | [10.9](/filings/0000950170-25-062744.md) | [9.5 d](/filings/0001437749-26-004219.md) | [12.1](/filings/0001437749-26-004220.md) | [13.6](/filings/0001437749-26-004221.md) | [10.7](/filings/0001437749-26-015199.md) | [11.5 d](/filings/0001437749-26-029098.md) | [11.4](/filings/0001437749-26-004220.md) | [10.7](/filings/0001437749-26-004221.md) | [8.2](/filings/0001437749-26-015199.md) | [7.7 d](/filings/0001437749-26-029098.md) |
| Operating income | $m | [2.2](/filings/0000950170-24-122358.md) | [(4.0)](/filings/0000950170-25-014485.md) | [(4.6)](/filings/0000950170-25-062744.md) | [6.8 d](/filings/0001437749-26-004219.md) | [(2.1)](/filings/0001437749-26-004220.md) | [4.7](/filings/0001437749-26-004221.md) | [1.0](/filings/0001437749-26-015199.md) | [4.2 d](/filings/0001437749-26-029098.md) | [(11.3)](/filings/0001437749-26-004220.md) | [(11.6)](/filings/0001437749-26-004221.md) | [(9.1)](/filings/0001437749-26-015199.md) | [5.5 d](/filings/0001437749-26-029098.md) |
| Interest expense | $m | [2.9](/filings/0000950170-24-122358.md) | [2.9](/filings/0000950170-25-014485.md) | [2.9](/filings/0000950170-25-062744.md) | [2.9 d](/filings/0001193125-25-191242.md) | [3.0](/filings/0001193125-25-266985.md) | [2.9](/filings/0000950170-25-014485.md) | [2.9](/filings/0000950170-25-062744.md) | [4.2 d](/filings/0001193125-25-191242.md) | [8.1](/filings/0001193125-25-266985.md) | [7.7](/filings/0001437749-26-004221.md) | [8.4](/filings/0001437749-26-015199.md) | [8.7 d](/filings/0001437749-26-029098.md) |
| Income tax | $m | [1.9](/filings/0000950170-24-122358.md) | [0.9](/filings/0000950170-25-014485.md) | [0.4](/filings/0000950170-25-062744.md) | [0.5 d](/filings/0001437749-26-004219.md) | [0.6](/filings/0001437749-26-004220.md) | [0.7](/filings/0001437749-26-004221.md) | [0.5](/filings/0001437749-26-015199.md) | [0.9 d](/filings/0001437749-26-029098.md) | [0.5](/filings/0001437749-26-004220.md) | [0.6](/filings/0001437749-26-004221.md) | [0.5](/filings/0001437749-26-015199.md) | [0.4 d](/filings/0001437749-26-029098.md) |
| Net income | $m | [(3.0)](/filings/0000950170-25-062744.md) | [(9.6)](/filings/0000950170-25-062744.md) | [(6.3)](/filings/0000950170-25-062744.md) | [3.4 d](/filings/0001437749-26-004219.md) | [(4.0)](/filings/0001437749-26-015199.md) | [2.5](/filings/0001437749-26-015199.md) | [(1.3)](/filings/0001437749-26-015199.md) | [1.1 d](/filings/0001437749-26-029098.md) | [(21.7)](/filings/0001437749-26-015199.md) | [(13.8)](/filings/0001437749-26-015199.md) | [(11.8)](/filings/0001437749-26-015199.md) | [(1.9) d](/filings/0001437749-26-029098.md) |
| Diluted EPS | $ per share | [(0.03)](/filings/0000950170-24-122358.md) | [(0.10)](/filings/0000950170-25-014485.md) | [(0.06)](/filings/0000950170-25-062744.md) | not reported | [(0.04)](/filings/0001193125-25-266985.md) | [0.02](/filings/0001437749-26-004221.md) | [(0.01)](/filings/0000950170-25-062744.md) | not reported | [(0.18)](/filings/0001193125-25-266985.md) | [(0.11)](/filings/0001437749-26-004221.md) | not reported | not reported |
| Basic EPS | $ per share | [(0.03)](/filings/0000950170-24-122358.md) | [(0.10)](/filings/0000950170-25-014485.md) | [(0.06)](/filings/0000950170-25-062744.md) | not reported | [(0.04)](/filings/0001437749-26-004220.md) | [0.03](/filings/0001437749-26-004221.md) | [(0.01)](/filings/0001437749-26-015199.md) | not reported | [(0.18)](/filings/0001437749-26-004220.md) | [(0.11)](/filings/0001437749-26-004221.md) | [(0.09)](/filings/0001437749-26-015199.md) | not reported |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfRevenue
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q1 FY2024 (2023-09-30) | Q2 FY2024 (2023-12-31) | Q3 FY2024 (2024-03-31) | FY2024 (2024-06-30) | Q1 FY2025 (2024-09-30) | Q2 FY2025 (2024-12-31) | Q3 FY2025 (2025-03-31) | FY2025 (2025-06-30) | Q1 FY2026 (2025-09-30) | Q2 FY2026 (2025-12-31) | Q3 FY2026 (2026-03-31) | FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [76.9](/filings/0000950170-23-060271.md) | [72.8](/filings/0000950170-24-012210.md) | [60.5](/filings/0000950170-24-055736.md) | [68.6](/filings/0001437749-26-004219.md) | [59.2](/filings/0000950170-24-122358.md) | [62.6](/filings/0000950170-25-014485.md) | [77.8](/filings/0000950170-25-062744.md) | [57.4](/filings/0001437749-26-029098.md) | [63.3](/filings/0001437749-26-004220.md) | [41.3](/filings/0001437749-26-004221.md) | [38.1](/filings/0001437749-26-015199.md) | [40.6](/filings/0001437749-26-029098.md) |
| Current assets | $m | [334](/filings/0000950170-23-060271.md) | [331](/filings/0000950170-24-012210.md) | [314](/filings/0000950170-24-055736.md) | [323](/filings/0001437749-26-004219.md) | [330](/filings/0000950170-24-122358.md) | [326](/filings/0000950170-25-014485.md) | [333](/filings/0000950170-25-062744.md) | [317](/filings/0001437749-26-029098.md) | [304](/filings/0001437749-26-004220.md) | [292](/filings/0001437749-26-004221.md) | [293](/filings/0001437749-26-015199.md) | [288](/filings/0001437749-26-029098.md) |
| Total assets | $m | [477](/filings/0000950170-23-060271.md) | [476](/filings/0000950170-24-012210.md) | [463](/filings/0000950170-24-055736.md) | [469](/filings/0001437749-26-004219.md) | [473](/filings/0000950170-24-122358.md) | [478](/filings/0000950170-25-014485.md) | [484](/filings/0000950170-25-062744.md) | [470](/filings/0001437749-26-029098.md) | [457](/filings/0001437749-26-004220.md) | [448](/filings/0001437749-26-004221.md) | [448](/filings/0001437749-26-015199.md) | [444](/filings/0001437749-26-029098.md) |
| Current liabilities | $m | [201](/filings/0000950170-23-060271.md) | [209](/filings/0000950170-24-012210.md) | [198](/filings/0000950170-24-055736.md) | [195](/filings/0001437749-26-004219.md) | [202](/filings/0000950170-24-122358.md) | [201](/filings/0000950170-25-014485.md) | [203](/filings/0000950170-25-062744.md) | [193](/filings/0001437749-26-029098.md) | [195](/filings/0001437749-26-004220.md) | [199](/filings/0001437749-26-004221.md) | [206](/filings/0001437749-26-015199.md) | [191](/filings/0001437749-26-029098.md) |
| Total liabilities | $m | [426](/filings/0000950170-23-060271.md) | [429](/filings/0000950170-24-012210.md) | [421](/filings/0000950170-24-055736.md) | [424](/filings/0001437749-26-004219.md) | [428](/filings/0000950170-24-122358.md) | [430](/filings/0000950170-25-014485.md) | [435](/filings/0000950170-25-062744.md) | [389](/filings/0001437749-26-029098.md) | [395](/filings/0001437749-26-004220.md) | [395](/filings/0001437749-26-004221.md) | [406](/filings/0001437749-26-015199.md) | [402](/filings/0001437749-26-029098.md) |
| Long-term debt | $m | [170](/filings/0000950170-23-060271.md) | [168](/filings/0000950170-24-012210.md) | [166](/filings/0000950170-24-055736.md) | [164](/filings/0001437749-26-004219.md) | [162](/filings/0000950170-24-122358.md) | [168](/filings/0000950170-25-014485.md) | [166](/filings/0000950170-25-062744.md) | [124](/filings/0001437749-26-029098.md) | [127](/filings/0001437749-26-004220.md) | [125](/filings/0001437749-26-004221.md) | [134](/filings/0001437749-26-015199.md) | [146](/filings/0001437749-26-029098.md) |
| Current portion of debt | $m | [6.2](/filings/0000950170-23-060271.md) | [6.7](/filings/0000950170-24-012210.md) | [7.2](/filings/0000950170-24-055736.md) | [7.8](/filings/0001437749-26-004219.md) | [7.8](/filings/0000950170-24-122358.md) | [7.6](/filings/0000950170-25-014485.md) | [7.6](/filings/0000950170-25-062744.md) | [12.7](/filings/0001437749-26-029098.md) | [12.9](/filings/0001437749-26-004220.md) | [11.1](/filings/0001437749-26-004221.md) | [11.2](/filings/0001437749-26-015199.md) | [1.5](/filings/0001437749-26-029098.md) |
| Short-term borrowings | $m | [6.2](/filings/0000950170-23-060271.md) | [6.7](/filings/0000950170-24-012210.md) | [7.2](/filings/0000950170-24-055736.md) | [7.8](/filings/0001193125-25-191242.md) | [7.8](/filings/0000950170-24-122358.md) | [7.6](/filings/0000950170-25-014485.md) | [7.6](/filings/0000950170-25-062744.md) | [12.7](/filings/0001193125-25-266985.md) | [12.9](/filings/0001193125-25-266985.md) | not reported | not reported | not reported |
| Shareholders' equity | $m | [50.9](/filings/0000950170-25-062744.md) | [47.7](/filings/0000950170-25-062744.md) | [41.1](/filings/0000950170-25-062744.md) | [45.1](/filings/0001437749-26-029098.md) | [45.2](/filings/0001437749-26-015199.md) | [47.9](/filings/0001437749-26-015199.md) | [49.6](/filings/0001437749-26-015199.md) | [81.2](/filings/0001437749-26-029098.md) | [61.9](/filings/0001437749-26-015199.md) | [53.4](/filings/0001437749-26-015199.md) | [41.7](/filings/0001437749-26-015199.md) | [41.7](/filings/0001437749-26-029098.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Short-term borrowings: us-gaap:ShortTermBorrowings
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q1 FY2024 (2023-09-30) | Q2 FY2024 (2023-12-31) | Q3 FY2024 (2024-03-31) | Q4 FY2024 (2024-06-30) | Q1 FY2025 (2024-09-30) | Q2 FY2025 (2024-12-31) | Q3 FY2025 (2025-03-31) | Q4 FY2025 (2025-06-30) | Q1 FY2026 (2025-09-30) | Q2 FY2026 (2025-12-31) | Q3 FY2026 (2026-03-31) | Q4 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(8.6)](/filings/0000950170-24-122358.md) | [(5.1) d](/filings/0000950170-25-014485.md) | [(8.1) d](/filings/0000950170-25-062744.md) | [9.9 d](/filings/0001437749-26-004219.md) | [(7.3)](/filings/0001437749-26-004220.md) | [1.8 d](/filings/0001437749-26-004221.md) | [18.1 d](/filings/0001437749-26-015199.md) | [(9.7) d](/filings/0001437749-26-029098.md) | [12.2](/filings/0001437749-26-004220.md) | [(16.0) d](/filings/0001437749-26-004221.md) | [(5.6) d](/filings/0001437749-26-015199.md) | [2.4 d](/filings/0001437749-26-029098.md) |
| Capital expenditure | $m | [1.1](/filings/0000950170-24-122358.md) | [1.2 d](/filings/0000950170-25-014485.md) | [0.8 d](/filings/0000950170-25-062744.md) | [0.5 d](/filings/0001437749-26-004219.md) | [1.1](/filings/0001437749-26-004220.md) | [0.9 d](/filings/0001437749-26-004221.md) | [1.0 d](/filings/0001437749-26-015199.md) | [1.3 d](/filings/0001437749-26-029098.md) | [1.9](/filings/0001437749-26-004220.md) | [3.0 d](/filings/0001437749-26-004221.md) | [0.5 d](/filings/0001437749-26-015199.md) | [0.5 d](/filings/0001437749-26-029098.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-03-31) | Q1 FY2023 (2022-09-30) | Q2 FY2023 (2022-12-31) | Q3 FY2023 (2023-03-31) | Q1 FY2024 (2023-09-30) | Q2 FY2024 (2023-12-31) | Q3 FY2024 (2024-03-31) | Q1 FY2025 (2024-09-30) | Q2 FY2025 (2024-12-31) | Q3 FY2025 (2025-03-31) | Q1 FY2026 (2025-09-30) | Q2 FY2026 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [92.8](/filings/0000950170-23-018808.md) | [93.5](/filings/0000950170-23-060271.md) | [94.6](/filings/0000950170-24-012210.md) | [97.5](/filings/0000950170-24-055736.md) | [96.6](/filings/0000950170-24-122358.md) | [97.8](/filings/0000950170-25-014485.md) | [99.2](/filings/0000950170-25-062744.md) | [100](/filings/0001193125-25-266985.md) | [0.1](/filings/0001437749-26-004221.md) | [103](/filings/0000950170-25-062744.md) | [119](/filings/0001193125-25-266985.md) | [0.1](/filings/0001437749-26-004221.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 119,439,307 at 2026-08-21, from the cover of the [10-K filed 2026-08-27](/filings/0001437749-26-029098.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:34 ET. No prices; not investment advice.